Why Are Pliant Therapeutics Shares Rallying Today?

Pliant Therapeutics Inc's  (NASDAQ: PLRX ) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints . The data demonstrated that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile.  A pooled analysis of PLN-74809 treated patients showed ... Full story available on Benzinga.com